LeoMed’s Innovational Product Are Certified by the United States Food and Drug Administration (FDA)
On June 26, 2018, LeoMed’s innovational product—ligating device—was certified by the United States Food and Drug Administration (FDA).
The ligating device represents an innovation of Leo Med. It is applicable to polypus ligation and trauma suturing in gastrointestinal endoscope operation. The split delivery system and the unique dual-loop design enable the ligating device to finish polypus ligation and trauma suturing in single-channel endoscope.
The FDA certification has been known as the “Guardian Angel of Americans’ Health.” Its huge influence is not restricted to the United States and other parts of North America. In fact, the FDA certification has been recognized throughout the world. Because the FDA certification has been acknowledged by the World Health Organization the highest certification standard of foods, drugs and medical instruments throughout the world, the FDA-certified enterprise will greatly improve its GMP management level and product quality level. Therefore, professionalism of the FDA certification has won trust from both experts and the public.
The ligating device is the first product of Leo Med, which is approved by the FDA. This has not only given us tremendous encouragement and confidence, but also laid a solid foundation for our exploration of the North American market. So far, LeoMed has been providing quality gastrointestinal endoscope products for doctors and patients from more than 54 countries and spanning six continents. The FDA’s approval of our ligating device will further motivate us to keep on exploring and innovating, seize more share on the international market, and head towards the goal of alleviating pains of more patients in the world.